Synopsys, whose software is used by semiconductor firms to design and verify chips, has benefited from surging investment ...
Zacks Investment Research on MSN
Why is CRISPR Therapeutics (CRSP) up 3.3% since last earnings report?
It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 3.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback